Souêtre, E <br/><br/>
Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.  [electronic resource] 

 -  PharmacoEconomics  1994 
 - 36-43 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1170-7690 
<br/><br/><label>Standard No.: </label>10.2165/00019053-199400062-00007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--economics<br/>Adolescent<br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Chemotherapy, Adjuvant<br/>Double-Blind Method<br/>Female<br/>France<br/>Granulocyte Colony-Stimulating Factor--economics<br/>Hospitalization--economics<br/>Humans<br/>Lenograstim<br/>Lymphoma, Non-Hodgkin--complications<br/>Male<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Prospective Studies<br/>Recombinant Proteins--economics